Camille Evrard

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer

Astrid Guyot d’Asnières de Salins, Gaëlle Tachon, Romain Cohen et al. · ESMO Open · 2021 · 109 citations · Full text

Medicine, Oncology, Pathology +17

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

David Tougeron, Benjamin Sueur, Aziz Zaanan et al. · International Journal of Cancer · 2020 · 77 citations · Full text

Medicine, Biostatistics, Oncology +15

Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor

Louis de Mestier, Thomas Walter, Camille Evrard et al. · Neuroendocrinology · 2019 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses

Louis de Mestier, Thomas Walter, Hédia Brixi et al. · Neuroendocrinology · 2019 · 50 citations

Medicine, Oncology, Pharmacotherapy +16